StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Oncology Biosimilars Portfolio by Quarter

Oncology Biosimilars Portfolio (Ruxience, Zirabev, Trazimera, Nivestym, Nyvepria) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Oncology Biosimilars Portfolio: $359M in Q2 2026, up 1.7% from a year earlier.

Latest, Q2 2026
359
Period ended Jun 28, 2026
Change on a year earlier
+1.7%
353 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
10
Documents cited below

Where the Q2 2026 figure comes from

“|| Oncology biosimilars (h) | 359 | 353 | 2% | 1% | 249 | 257 | (3%) | 110 | 97 | 14% | 11%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOncology Biosimilars Portfolio (Ruxience, Zirabev, Trazimera, Nivestym, Nyvepria) — Worldwide revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 2026359+1.7%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 2026409+54.9%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 2025369+76.6%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 2025315+10.5%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 2025353+26.5%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 20252640.0%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 2024209-35.1%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 2024285-8.1%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 2024279-23.1%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024264-35.9%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 2023322–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 2023310–Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 2023363–Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 2023412–Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗

Breakdown

What makes up oncology Biosimilars Portfolio

Cite this data

StockData. (2026). Pfizer Oncology Biosimilars Portfolio ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/onc-biosim-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.